Breaking News Instant updates and real-time market news.

ADMP

Adamis Pharmaceuticals

$1.30

0.04 (3.17%)

, NVS

Novartis

$90.76

0.29 (0.32%)

08:35
07/09/19
07/09
08:35
07/09/19
08:35

Adamis Pharmaceuticals provides update on U.S. retail launch of SYMJEPI

Adamis Pharmaceuticals Corporation (ADMP) provided an update that Sandoz, a Novartis (NVS) division, announced the U.S. retail launch of SYMJEPI 0.3 mg and 0.15 mg Injections, making both the adult and pediatric doses immediately available in local pharmacies across the U.S. Sandoz launched SYMJEPI 0.3 mg Injection in the institutional channel earlier this year, and large wholesaler customers of Sandoz are now fully stocked to supply hospitals and clinics with both SYMJEPI 0.3 mg and 0.15 mg Injections inventory in the U.S.

ADMP

Adamis Pharmaceuticals

$1.30

0.04 (3.17%)

NVS

Novartis

$90.76

0.29 (0.32%)

  • 11

    Jul

  • 22

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Sep

ADMP Adamis Pharmaceuticals
$1.30

0.04 (3.17%)

08/23/18
HCWC
08/23/18
NO CHANGE
Target $7
HCWC
Buy
Adamis selloff on generic EpiPen a buying opportunity, says H.C. Wainwright
Recent weakness in shares of Adamis Pharmaceuticals (ADMP) appears related to news that Teva (TEVA) has received approval to launch a generic version of Mylan's (MYL) EpiPen, H.C. Wainwright analyst Jason Kolbert tells investors in a research note. Sandoz, Adamis' partner, is well aware of Teva's initiatives and remains committed to the launch of Adamis' Symjepi, the analyst adds, As such, he views the recent pullback in Adamis as a buying opportunity. He lowered his price target for the stock to $7 from $10 and keeps a Buy rating on the name.
11/12/18
RILY
11/12/18
DOWNGRADE
Target $2.5
RILY
Neutral
Adamis Pharmaceuticals downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva downgraded Adamis Pharmaceuticals to Neutral and lowered his price target for the shares to $2.50 from $7.50. The analyst cites the company's Q3 results for moving him to the sidelines.
NVS Novartis
$90.76

0.29 (0.32%)

06/03/19
06/03/19
DOWNGRADE

Perform
Aduro Biotech downgraded to Perform on lack of catalysts at Oppenheimer
As previously reported, Oppenheimer analyst Mark Breidenbach downgraded Aduro Biotech (ADRO) to Perform from Outperform given the company's lack of near-term catalysts. The analyst notes that Aduro's partner Novartis (NVS) presented initial clinical results from an ongoing Phase 1b trial of ADU-S100 in combination with spartalizumab in advanced tumors at ASCO. Given the pretreatment history of these patients, he cannot state with confidence that the responses observed were dependent on ADUS100, and the trial data suggests dosing has not yet been fully optimized. As Novartis continues to evaluate the STING agonist, Breidenbach anticipates an extended development timeline.
06/14/19
PIPR
06/14/19
NO CHANGE
Target $120
PIPR
Neutral
Price tag of Bluebird's Zynteglo 'hard to justify,' says Piper Jaffray
The $1.8M price tag of Bluebird Bio's Zynteglo is "hard to justify" given the $2.1M comp of Novartis' (NVS) Zolgensma, which treats children with a certain outcome of death, as opposed to a population where the majority of patients are adequately maintained on transfusions, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. In Zynteglo clinical trials, only 60 beta-thal patients have been enrolled and 16 sickle cell patients have ever been infused, the analyst points out. Yet, says Van Buren, the Street is modeling that Bluebird transplants thousands of patients with Zynteglo. He continues to believe uptake of the gene therapy will be challenging and keeps a Neutral rating on Bluebird Bio with a $120 price target.
06/18/19
06/18/19
DOWNGRADE

Hold
Regeneron downgraded to Hold at Argus on mounting threats to Eylea
As previously reported, Argus analyst Jasper Hellweg downgraded Regeneron (REGN) to Hold from Buy, saying that while the company has a "strong pipeline" with new recent indications for multiple products, its primary revenue driver Eylea is facing several competitive threats. The analyst notes that Novartis (NVS) could launch a biologic designed to treat Eylea's key indication of wet age-related macular degeneration by the end of Q2 and also notes that the drug's patents are set to expire in 2022 in China and Japan, 2023 in the U.S., and 2024 in Europe. Hellweg adds that he will return his Regeneron rating to Buy if the company demonstrates that it can offset the impact of reduced Eylea sales, which accounted for over 75% of total revenue in Q1.
06/28/19
PIPR
06/28/19
DOWNGRADE
Target $250
PIPR
Neutral
Biogen downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Christopher Raymond downgraded Biogen (BIIB) to Neutral from Overweight and lowered his price target for the shares to $250 from $280. The stock closed yesterday up $1.70 to $239.77. Piper's new neurologist survey data from Spherix Global Insights "spells bad news for both Tecfidera and Tysabri in the near and longer term," Raymond tells investors in a research note. For the first time in a long time, Tecfidera market share is projected to contract over the next six months, primarily at the hands of Novartis' (NVS) new entrant Mayzent, explains the analyst. Further, Raymond notes that while prior surveys have indicated a plateauing of Roche's (RHHBY) Ocrevus with Biogen's Tysabri "hanging in there," the most recent indications are for an accelerating Ocrevus with Tysabri the "clear loser." The analyst lowered his estimates for both Tecfidera and Tysabri and downgraded Biogen.

TODAY'S FREE FLY STORIES

MSFT

Microsoft

$135.02

-1.21 (-0.89%)

, AMZN

Amazon.com

$1,958.83

-33.58 (-1.69%)

14:05
07/18/19
07/18
14:05
07/18/19
14:05
Periodicals
Trump says he's considering looking into Pentagon's JEDI contract, CNBC says »

U.S. President Donald…

MSFT

Microsoft

$135.02

-1.21 (-0.89%)

AMZN

Amazon.com

$1,958.83

-33.58 (-1.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 25

    Jul

  • 06

    Aug

  • 08

    Aug

EGBN

Eagle Bancorp

$44.62

-8.81 (-16.49%)

14:02
07/18/19
07/18
14:02
07/18/19
14:02
Downgrade
Eagle Bancorp rating change  »

Eagle Bancorp downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 15

    Aug

  • 11

    Sep

  • 23

    Sep

14:00
07/18/19
07/18
14:00
07/18/19
14:00
General news
Breaking General news story  »

New York Federal Reserve…

13:55
07/18/19
07/18
13:55
07/18/19
13:55
Conference/Events
Federal Reserve Bank of New York president delivers keynote address »

New York Federal Reserve…

CAMP

CalAmp

$10.59

-0.23 (-2.13%)

13:55
07/18/19
07/18
13:55
07/18/19
13:55
Conference/Events
CalAmp participates in a conference call with Northland »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Jul

  • 06

    Aug

ADMP

Adamis Pharmaceuticals

$1.22

-0.03 (-2.41%)

13:54
07/18/19
07/18
13:54
07/18/19
13:54
Hot Stocks
Adamis Pharmaceuticals, kaleo Inc agree to settle all litigation »

Adamis Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

PPG

PPG

$116.58

-0.025 (-0.02%)

13:54
07/18/19
07/18
13:54
07/18/19
13:54
Earnings
PPG sees unfavorable currency translation impact on Q3 sales of $30M-$50M »

"Looking ahead,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Aug

PPG

PPG

$116.49

-0.115 (-0.10%)

13:49
07/18/19
07/18
13:49
07/18/19
13:49
Hot Stocks
PPG says Q2 EPS impacted by lower global industrial production »

According to prepared…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 05

    Aug

ZBRA

Zebra Technologies

$180.92

-16.74 (-8.47%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Options
Notable vol spike in Zebra Technologies as shares sell off »

Notable vol spike in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$6.98

0.31 (4.65%)

13:40
07/18/19
07/18
13:40
07/18/19
13:40
Recommendations
Tellurian analyst commentary at Stifel »

Tellurian higher after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JLL

Jones Lang LaSalle

$140.05

0.585 (0.42%)

13:32
07/18/19
07/18
13:32
07/18/19
13:32
Conference/Events
Jones Lang LaSalle management to meet with Mizuho »

Meeting with EVP Monahan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 06

    Aug

  • 06

    Aug

GOSS

Gossamer Bio

$19.60

-0.48 (-2.39%)

13:30
07/18/19
07/18
13:30
07/18/19
13:30
Options
Gossamer Bio call volume spikes on November purchase wit shares at 52wk lows »

Gossamer Bio call volume…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:25
07/18/19
07/18
13:25
07/18/19
13:25
Conference/Events
Cowen healthcare/biotech analysts to hold an analyst/industry conference call »

Healthcare Technology…

PEP

PepsiCo

$132.17

-0.6 (-0.45%)

13:24
07/18/19
07/18
13:24
07/18/19
13:24
Periodicals
Breaking Periodicals news story on PepsiCo »

PepsiCo in talks to buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:20
07/18/19
07/18
13:20
07/18/19
13:20
General news
Treasury's $14 B 10-year TIPS sale was on the soft side »

Treasury's $14 B…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

13:17
07/18/19
07/18
13:17
07/18/19
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

13:16
07/18/19
07/18
13:16
07/18/19
13:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNIT

Uniti Group

$8.55

-0.03 (-0.35%)

13:15
07/18/19
07/18
13:15
07/18/19
13:15
Options
Uniti Group put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Coupon Rate data reported »

10-Yr TIPS Auction Coupon…

13:09
07/18/19
07/18
13:09
07/18/19
13:09
General news
10-Yr TIPS Auction Total Amount data reported »

10-Yr TIPS Auction Total…

TELL

Tellurian

$6.99

0.32 (4.80%)

13:05
07/18/19
07/18
13:05
07/18/19
13:05
Options
Tellurian call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:57
07/18/19
07/18
12:57
07/18/19
12:57
Conference/Events
Stephens architecture analysts to hold analyst/industry conference call nosymbol »

Analysts hold an…

EMR

Emerson

$64.26

-0.4 (-0.62%)

12:55
07/18/19
07/18
12:55
07/18/19
12:55
Options
Emerson put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

  • 06

    Aug

  • 22

    Aug

  • 06

    Sep

12:45
07/18/19
07/18
12:45
07/18/19
12:45
General news
Treasury $14 B 10-year TIPS preview: the auction outlook is mixed. »

Treasury $14 B 10-year…

FB

Facebook

$200.15

-1.82 (-0.90%)

12:43
07/18/19
07/18
12:43
07/18/19
12:43
Periodicals
Instagram hiding 'likes' in more countries to ease pressure, Gadgets says »

Facebook's Instagram…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.